TREM-1 Antibodies

Santa Cruz Biotechnology offers a broad range of TREM-1 monoclonal antibodies for investigating Triggering Receptor Expressed on Myeloid Cells 1 (TREM-1). TREM-1 monoclonal antibodies are validated for multiple applications, including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). TREM-1 is a key receptor that amplifies inflammatory responses during infections and autoimmune diseases. Expression of TREM-1 occurs predominantly on myeloid cells, where it mediates immune responses and influences inflammatory condition severity. Research focused on TREM-1 continues to reveal important insights about immune system regulation and inflammatory processes. Understanding TREM-1's cellular mechanisms is crucial for developing new therapeutic approaches for inflammatory diseases. Investigating TREM-1 signaling pathways helps illuminate how immune responses are modulated during disease progression. Exploring TREM-1's role in different tissue environments provides valuable information about inflammatory disease mechanisms. Santa Cruz Biotechnology monoclonal antibodies enable researchers worldwide to advance scientific understanding of TREM-1's role in health and disease.